Climb Bio

CLYMNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$801.682 M

$14.00 +0.00%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$59.9M

Loss-making

Shares outstanding

57,436,255

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations — ranked by market cap

All 501 →

#174Kura OncologyKURA$849.6M
#175Aclaris TherapeuticsACRS$825.4M
#176Climb BioCLYM$801.7M
#177Monopar TherapeuticsMNPR$798.6M
#178Bright Minds BiosciencesDRUG$778.4M

Where these numbers come from

Share counts and financials for Climb Bio are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.